Discovery and Development of Dolastatin 10-Derived Antibody Drug Conjugate Anticancer Drugs
出版年份 2022 全文链接
标题
Discovery and Development of Dolastatin 10-Derived Antibody Drug Conjugate Anticancer Drugs
作者
关键词
-
出版物
JOURNAL OF NATURAL PRODUCTS
Volume -, Issue -, Pages -
出版商
American Chemical Society (ACS)
发表日期
2022-01-25
DOI
10.1021/acs.jnatprod.1c01135
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Natural Product Based Antibody Drug Conjugates: Clinical Status as of November 9, 2020
- (2021) David J. Newman JOURNAL OF NATURAL PRODUCTS
- A Novel c-MET-Targeting Antibody-Drug Conjugate for Pancreatic Cancer
- (2021) Yangbing Jin et al. Frontiers in Oncology
- First-in-Human Study of PF-06647020 (Cofetuzumab Pelidotin), an Antibody–Drug Conjugate Targeting Protein Tyrosine Kinase 7, in Advanced Solid Tumors
- (2021) Michael L. Maitland et al. CLINICAL CANCER RESEARCH
- Safety and unique pharmacokinetic profile of ARX788, a site-specific ADC, in heavily pretreated patients with HER2-overexpresing solid tumors: Results from two phase 1 clinical trials.
- (2021) Sara A. Hurvitz et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I study of A166 in patients with HER2-expressing locally advanced or metastatic solid tumors.
- (2021) Xichun Hu et al. JOURNAL OF CLINICAL ONCOLOGY
- A phase 1 multicenter, dose expansion study of ARX788 as monotherapy in patients with HER2-positive advanced gastric and gastroesophageal junction adenocarcinoma (ACE-Gastric-01).
- (2021) Yang Zhang et al. JOURNAL OF CLINICAL ONCOLOGY
- Marine Antitumor Peptide Dolastatin 10: Biological Activity, Structural Modification and Synthetic Chemistry
- (2021) Gang Gao et al. Marine Drugs
- Discovery of Dolastatinol: A Synthetic Analog of Dolastatin 10 and Low Nanomolar Inhibitor of Tubulin Polymerization
- (2021) Hodaya Gutman et al. ACS Medicinal Chemistry Letters
- A phase I dose escalation study evaluating the safety and tolerability of a novel anti-HER2 antibody-drug conjugate (PF-06804103) in patients with HER2-positive solid tumors.
- (2020) Funda Meric-Bernstam et al. JOURNAL OF CLINICAL ONCOLOGY
- Antineoplastic Agents. 607. Emetine Auristatins
- (2020) George R. Pettit et al. JOURNAL OF NATURAL PRODUCTS
- Nonclinical Development of Next Generation Site-Specific HER2 Targeting Antibody Drug Conjugate (ARX788) for Breast Cancer Treatment
- (2020) Prathap Nagaraja Shastri et al. MOLECULAR CANCER THERAPEUTICS
- ARX788, a Site-specific anti-HER2 Antibody Drug Conjugate, Demonstrates Potent and Selective Activity in HER2 Low and T-DM1 Resistant Breast and Gastric Cancers
- (2020) Lillian Skidmore et al. MOLECULAR CANCER THERAPEUTICS
- PF-06804103, a site-specific anti-HER2 antibody-drug conjugate for the treatment of HER2-expressing breast, gastric, and lung cancers
- (2020) Edmund I. Graziani et al. MOLECULAR CANCER THERAPEUTICS
- Belantamab Mafodotin: First Approval
- (2020) Anthony Markham DRUGS
- Marine Compounds and Cancer: Updates 2020
- (2020) Sergey A. Dyshlovoy et al. Marine Drugs
- Novel Auristatins with High Bystander and Cytotoxic Activities in Drug-Efflux Positive Tumor Models
- (2020) Philip N. Moquist et al. MOLECULAR CANCER THERAPEUTICS
- SHR-A1403, a novel c-Met antibody-drug conjugate, exerts encouraging anti-tumor activity in c-Met-overexpressing models
- (2019) Chang-yong Yang et al. ACTA PHARMACOLOGICA SINICA
- Antitumor activity of a 5T4 targeting antibody drug conjugate with a novel payload derived from MMAF via C-Lock linker
- (2019) Baoying Shi et al. Cancer Medicine
- Discovery of a novel EGFR targeting antibody-drug conjugate, SHR-A1307, for the treatment of solid tumors resistant or refractory to anti-EGFR therapies
- (2019) Kaijie He et al. MOLECULAR CANCER THERAPEUTICS
- The “Utility” of Highly Toxic Marine-Sourced Compounds
- (2019) David J. Newman Marine Drugs
- SHR ‐A1403, a novel c‐mesenchymal‐epithelial transition factor (c‐Met) antibody‐drug conjugate, overcomes AZD 9291 resistance in non‐small cell lung cancer cells overexpressing c‐Met
- (2019) Mengya Tong et al. CANCER SCIENCE
- First-in-Human Phase I Study of Aprutumab Ixadotin, a Fibroblast Growth Factor Receptor 2 Antibody–Drug Conjugate (BAY 1187982) in Patients with Advanced Cancer
- (2019) Sung-Bae Kim et al. Targeted Oncology
- Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study
- (2019) Sagar Lonial et al. LANCET ONCOLOGY
- Synthesis and evaluation of novel dolastatin 10 derivatives for versatile conjugations
- (2018) Shinya Yokosaka et al. BIOORGANIC & MEDICINAL CHEMISTRY
- Metabolism of an Oxime-Linked Antibody Drug Conjugate, AGS62P1, and Characterization of Its Identified Metabolite
- (2018) Josh T. Snyder et al. MOLECULAR PHARMACEUTICS
- Synthesis and Evaluation of Dolastatin 10 Analogues Containing Heteroatoms on the Amino Acid Side Chains
- (2017) Julien Dugal-Tessier et al. JOURNAL OF NATURAL PRODUCTS
- Current Status of Marine-Derived Compounds as Warheads in Anti-Tumor Drug Candidates
- (2017) David Newman et al. Marine Drugs
- Preclinical Antitumor Efficacy of BAY 1129980—a Novel Auristatin-Based Anti-C4.4A (LYPD3) Antibody–Drug Conjugate for the Treatment of Non–Small Cell Lung Cancer
- (2017) Jörg Willuda et al. MOLECULAR CANCER THERAPEUTICS
- A practical approach to asymmetric synthesis of dolastatin 10
- (2017) Wen Zhou et al. ORGANIC & BIOMOLECULAR CHEMISTRY
- Synthesis and biological activity evaluation of dolastatin 10 analogues with N-terminal modifications
- (2017) Xin Wang et al. TETRAHEDRON
- Preclinical Efficacy of the Auristatin-Based Antibody–Drug Conjugate BAY 1187982 for the Treatment of FGFR2-Positive Solid Tumors
- (2016) Anette Sommer et al. CANCER RESEARCH
- Recent Advances in the Development of New Auristatins: Structural Modifications and Application in Antibody Drug Conjugates
- (2015) Andreas Maderna et al. MOLECULAR PHARMACEUTICS
- Discovery of Cytotoxic Dolastatin 10 Analogues with N-Terminal Modifications
- (2014) Andreas Maderna et al. JOURNAL OF MEDICINAL CHEMISTRY
- Marine-Sourced Anti-Cancer and Cancer Pain Control Agents in Clinical and Late Preclinical Development
- (2014) David Newman et al. Marine Drugs
- A Synthetic Dolastatin 10 Analogue Suppresses Microtubule Dynamics, Inhibits Cell Proliferation, and Induces Apoptotic Cell Death
- (2013) Praveen Kumar Gajula et al. JOURNAL OF MEDICINAL CHEMISTRY
- The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma
- (2012) Peter D Senter et al. NATURE BIOTECHNOLOGY
- Antineoplastic Agents. 592. Highly Effective Cancer Cell Growth Inhibitory Structural Modifications of Dolastatin 10
- (2011) George R. Pettit et al. JOURNAL OF NATURAL PRODUCTS
- A Straightforward Approach to Protected (S)-Dolaphenine (Doe), the Unusual Amino Acid Component of Dolastatin 10
- (2011) Uli Kazmaier et al. SYNTHESIS-STUTTGART
- Novel Peptide Linkers for Highly Potent Antibody−Auristatin Conjugate
- (2008) Svetlana O. Doronina et al. BIOCONJUGATE CHEMISTRY
- Phase I study of TZT-1027, a novel synthetic dolastatin 10 derivative, for the treatment of patients with non-small cell lung cancer
- (2008) J. Horti et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Phase I study of TZT-1027, a novel synthetic dolastatin 10 derivative and inhibitor of tubulin polymerization, given weekly to advanced solid tumor patients for 3 weeks
- (2008) Nobuyuki Yamamoto et al. CANCER SCIENCE
- Structural insight into the inhibition of tubulin by vinca domain peptide ligands
- (2008) Anthony Cormier et al. EMBO REPORTS
- Stereoselective synthesis of the dolastatin units by organotrifluoroborates additions to α-amino aldehydes
- (2007) Rodrigo Cella et al. TETRAHEDRON LETTERS
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More